OAP-189

Pfizer · Phase 1 active Small molecule

OAP-189 is a small molecule in Phase 1 development by Pfizer for Type 2 Diabetes. It has shown promise in initial safety and tolerability studies but lacks an FDA label. The drug is withdrawn from a study in obese subjects.

At a glance

Generic name	OAP-189
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OAP-189 CI brief — competitive landscape report
OAP-189 updates RSS · CI watch RSS
Pfizer portfolio CI